Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorofeyev

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Environmental Science and Pollution Research International|August 29, 2022
Gastrointestinal health: changes of intestinal mucosa and microbiota in patients with ulcerative colitis and irritable bowel syndrome from PM<sub>2.5</sub>-polluted regions of UkraineAndrey Dorofeyev, Anna Dorofeyeva, Arsenii Borysov, et al.
Gastroenterology Research and Practice|June 6, 2013
Mucosal barrier in ulcerative colitis and Crohn's diseaseA E Dorofeyev, I V Vasilenko, O A Rassokhina, et al.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|April 4, 2021
APPLICATION OF INTELLECTUAL MONITORING INFORMATION TECHNOLOGY IN DETERMINING THE SEVERITY OF THE CONDITION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASESAndriy E Dorofeyev, Sergiy V Holub, Gulustan H Babayeva, et al.
Frontiers in Medicine|November 7, 2022
Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: A randomized, clinical trialSergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, et al.
Microbiology (Reading, England)|March 13, 2021
Respiration of <i>Pseudomonas fluorescens</i> as a function of intracellular substrate concentrationAlexander G Dorofeyev, Michael J Bazin, James M Lynch, et al.
Clinical and Experimental Gastroenterology|July 15, 2011
Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndromeAndrey E Dorofeyev, Elena A Kiriyan, Inna V Vasilenko, et al.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|March 4, 2020
Genetic polymorphism in patients with early and late onset of ulcerative colitisAndriy E Dorofeyev, Anna A Dorofeyeva, Elena A Kiriyan, et al.
Medicina (Kaunas, Lithuania)|January 21, 2022
Current Status and Future Therapeutic Options for Fecal Microbiota TransplantationSergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, et al.
Frontiers in Medicine|January 30, 2023
Efficacy and safety of fecal microbiota transplantation <i>via</i> colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trialSergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, et al.
United European Gastroenterology Journal|February 14, 2018
Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trialAxel Dignass, Robert Schnabel, Jacek Romatowski, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Environmental Science and Pollution Research International|August 29, 2022
Gastrointestinal health: changes of intestinal mucosa and microbiota in patients with ulcerative colitis and irritable bowel syndrome from PM<sub>2.5</sub>-polluted regions of UkraineAndrey Dorofeyev, Anna Dorofeyeva, Arsenii Borysov, et al.
Gastroenterology Research and Practice|June 6, 2013
Mucosal barrier in ulcerative colitis and Crohn's diseaseA E Dorofeyev, I V Vasilenko, O A Rassokhina, et al.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|April 4, 2021
APPLICATION OF INTELLECTUAL MONITORING INFORMATION TECHNOLOGY IN DETERMINING THE SEVERITY OF THE CONDITION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASESAndriy E Dorofeyev, Sergiy V Holub, Gulustan H Babayeva, et al.
Frontiers in Medicine|November 7, 2022
Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: A randomized, clinical trialSergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, et al.
Microbiology (Reading, England)|March 13, 2021
Respiration of <i>Pseudomonas fluorescens</i> as a function of intracellular substrate concentrationAlexander G Dorofeyev, Michael J Bazin, James M Lynch, et al.
Clinical and Experimental Gastroenterology|July 15, 2011
Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndromeAndrey E Dorofeyev, Elena A Kiriyan, Inna V Vasilenko, et al.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|March 4, 2020
Genetic polymorphism in patients with early and late onset of ulcerative colitisAndriy E Dorofeyev, Anna A Dorofeyeva, Elena A Kiriyan, et al.
Medicina (Kaunas, Lithuania)|January 21, 2022
Current Status and Future Therapeutic Options for Fecal Microbiota TransplantationSergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, et al.
Frontiers in Medicine|January 30, 2023
Efficacy and safety of fecal microbiota transplantation <i>via</i> colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trialSergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, et al.
United European Gastroenterology Journal|February 14, 2018
Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trialAxel Dignass, Robert Schnabel, Jacek Romatowski, et al.
Pageof 4